open access

Vol 21, No 1 (2014)
Original articles
Published online: 2013-04-26
Get Citation

Factor XIII Val34Leu polymorphism in patients with cardiac syndrome X

Gamze Babur Güler, Ulaankhuu Batgerel, Ekrem Güler, Oğuz Karaca, Çetin Geçmen, Hacı Murat Güneş, Hicaz Zencirkıran Aguş, Ali Metin Esen, Mehmet Muhsin Türkmen
DOI: 10.5603/CJ.a2013.0046
·
Cardiol J 2014;21(1):6-10.

open access

Vol 21, No 1 (2014)
Original articles
Published online: 2013-04-26

Abstract

Background: The aim of the study was to examine the frequency of factor XIII polymorphism among patients with cardiac syndrome X (CSX).

Methods: This study was designed as a cross-sectional and observational study. Forty-eight female patients with CSX and 36 controls matched by age, gender, diabetes, and hypertension were studied. CSX was defined as typical chest pain during rest or effort, abnormal test result for exercise ECG, and presence of angiographically normal epicardial coronary arteries after ruling out inducible spasm. Factor XIII gene polymorphism was investigated by using CVD Strip Assay (ViennaLab Diagnostic GmbH) commercial kit.

Results: The frequency of factor XIII (Val/Leu + Leu/Leu) mutation was significantly higher in patients with CSX (43%) than in controls (19%) (p = 0.02). Frequency of the Leu allele was significantly higher in the patient group (23.5% vs. 11.1%, p = 0.04). Factor XIII (Val/Leu + Leu/Leu) mutation (p = 0.01, OR = 3.42; 95% CI 1.22–9.58) and smoking (p = 0.04, OR = 3.33, 95% CI 1.05–10.58) were identified as independent predictors of the disease in multivariate regression analysis.

Conclusions: This study indicates that there is an evidence for association between factor XIII Val34Leu polymorphism and CSX.

Abstract

Background: The aim of the study was to examine the frequency of factor XIII polymorphism among patients with cardiac syndrome X (CSX).

Methods: This study was designed as a cross-sectional and observational study. Forty-eight female patients with CSX and 36 controls matched by age, gender, diabetes, and hypertension were studied. CSX was defined as typical chest pain during rest or effort, abnormal test result for exercise ECG, and presence of angiographically normal epicardial coronary arteries after ruling out inducible spasm. Factor XIII gene polymorphism was investigated by using CVD Strip Assay (ViennaLab Diagnostic GmbH) commercial kit.

Results: The frequency of factor XIII (Val/Leu + Leu/Leu) mutation was significantly higher in patients with CSX (43%) than in controls (19%) (p = 0.02). Frequency of the Leu allele was significantly higher in the patient group (23.5% vs. 11.1%, p = 0.04). Factor XIII (Val/Leu + Leu/Leu) mutation (p = 0.01, OR = 3.42; 95% CI 1.22–9.58) and smoking (p = 0.04, OR = 3.33, 95% CI 1.05–10.58) were identified as independent predictors of the disease in multivariate regression analysis.

Conclusions: This study indicates that there is an evidence for association between factor XIII Val34Leu polymorphism and CSX.

Get Citation

Keywords

cardiac syndrome X, factor XIII polymorphism

About this article
Title

Factor XIII Val34Leu polymorphism in patients with cardiac syndrome X

Journal

Cardiology Journal

Issue

Vol 21, No 1 (2014)

Pages

6-10

Published online

2013-04-26

DOI

10.5603/CJ.a2013.0046

Bibliographic record

Cardiol J 2014;21(1):6-10.

Keywords

cardiac syndrome X
factor XIII polymorphism

Authors

Gamze Babur Güler
Ulaankhuu Batgerel
Ekrem Güler
Oğuz Karaca
Çetin Geçmen
Hacı Murat Güneş
Hicaz Zencirkıran Aguş
Ali Metin Esen
Mehmet Muhsin Türkmen

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl